Ligand id: 4582

Name: canagliflozin

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: canagliflozin

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 4
Rotatable bonds 5
Topological polar surface area 118.39
Molecular weight 444.14
XLogP 5.03
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Canagliflozin is an anti-diabetic drug, used to improve glycemic control in adults with type 2 diabetes mellitus. Canagliflozin is combined with metformin in Invokamet®, the first fixed-dose combination of an SGLT2 inhibitor with metformin to be approved (by the US FDA, 2014).
Mechanism Of Action and Pharmacodynamic Effects
Canagliflozin inhibits the sodium/glucose cotransporter 2 (SLC5A2). Inhibition of this transporter in the proximal renal tubules reduces reabsorption of glucose, thereby increasing urinary glucose excretion.
External links